Prix Everest Medicines Limited (01952.HK)

Everest Medicines Ltd. is a biopharmaceutical company, which engages in the discovering, developing, manufacturing, and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asian markets. The company is headquartered in Shanghai, Shanghai and currently employs 722 full-time employees. The company went IPO on 2020-10-09. The firm has built a product pipeline across renal, anti-infective, and autoimmune diseases. The Company’s products portfolio includes Nefecon (TARPEYO) using in the renal therapeutic area, XERAVA (eravacycline) using in the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant isolates and other products. The firm conducts its business in the domestic and overseas markets.